ABBV vs NFLX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Netflix, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
Netflix, Inc. · Communication Services
$91.02
+95.7% upside to fair value
Grade B
High Quality
QuantHub Verdict
NFLX has more upside to fair value
(+95.7%).
NFLX trades at a lower forward P/E
(28.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NFLX |
| Current Price |
$197.69 |
$91.02 |
| Fair Value Estimate |
$219.51 |
$178.10 |
| Upside to Fair Value |
+11.0%
|
+95.7%
|
| Market Cap |
$349.7B |
$383.3B |
| Forward P/E |
83.3x
|
28.7x
|
| EV / EBITDA |
23.4x
|
11.4x
|
| Price / Sales |
5.7x
|
8.2x
|
| Price / FCF |
18.7x
|
32.2x
|
| Revenue Growth YoY |
+10.0%
|
+16.2%
|
| Gross Margin |
70.2%
|
49.0%
|
| Operating Margin |
26.7%
|
29.7%
|
| Return on Equity |
-361.6%
|
49.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.1%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Netflix, Inc. operates a leading global streaming entertainment service with a dominant streaming segment accounting for nearly 100% of its revenue. The company benefits from a high-quality business model characterized by strong revenue growth of 16.2% and earnings growth of 82.8% in the most recent quarter, a robust 49.2% return on equity, and healthy margins with a 29.7% operating margin and 28…
Accumulation Zones
| Metric |
ABBV |
NFLX |
| Zone Low |
$164.63 |
$133.57 |
| Zone High |
$186.58 |
$151.38 |
| In Buy Zone? |
No
|
Yes
|